204,804 Shares in Boston Scientific Corporation $BSX Bought by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 204,804 shares of the medical equipment provider’s stock, valued at approximately $19,995,000.

Several other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in Boston Scientific in the 2nd quarter worth about $2,089,937,000. Edgewood Management LLC bought a new position in shares of Boston Scientific during the second quarter valued at approximately $746,655,000. Parnassus Investments LLC grew its stake in shares of Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after buying an additional 6,868,459 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after buying an additional 2,899,653 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after acquiring an additional 2,823,744 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.0%

NYSE BSX opened at $76.26 on Thursday. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market capitalization of $113.04 billion, a price-to-earnings ratio of 39.31, a price-to-earnings-growth ratio of 1.05 and a beta of 0.67. The company’s 50-day simple moving average is $89.90 and its two-hundred day simple moving average is $97.00.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The company’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BSX. Mizuho cut their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a report on Thursday, February 5th. Oppenheimer lowered their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Finally, Robert W. Baird dropped their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.